Evolving immunotherapy strategies in NSCLC
Views & Analysis
In his article in the latest edition of Deep Dive: Future Pharma, Ben Doran assesses the status of immunotherapy strategies in non-small cell lung cancer (NSCLC) and how marketers should leverage new combination strategies to meet unmet needs of specific patient populations and ensure market access as these new treatments evolve and take hold.
Points examined in his feature include:
- Years of research are beginning to result in significant gains in the standard of care (SoC), specifically for patients eligible for anti-PD-1 therapy.
- As all anti-PD-1s have the same pricing, the benefit of multiple approvals has not resulted in typical market behaviour.
- The future challenge is to define the immunotherapy landscape and combination rationale, with a personalised, patient-centric approach.
Read the full article here. Deep Dive is best viewed in full-screen mode.
Read the whole edition of Deep Dive: Future Pharma.
The next issue will be Deep Dive: Market Access II. Sign up for your complimentary subscription here.
